



#5
RECEIVED
EXCEPTION
AUG 23 2001
TECH CENTER 1600/2900
8/14/01

Patent Docket P1759R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of Avi J. Ashkenazi et al. Serial No.: 09/589,395 Filed: June 7, 2000 For: Apo-2L Receptor Agonist and CPT-11 Synergism</p>	<p>Group Art Unit: 1642 Examiner: G. Nickol</p> <p>CERTIFICATE OF Express MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service via Express Mail, Express Mail No. EL599583820US in an envelope to: Assistant Commissioner of Patents, Washington, D.C. 20231 on August 16, 2001 <i>Diane L. Marschang</i> Diane L. Marschang</p>
---	--

**RESPONSE TO RESTRICTION REQUIREMENT
AND
PRELIMINARY AMENDMENT**

Assistant Commissioner of Patents
Washington, D.C. 20231

SIR:

This paper is being filed in response to the Office Action mailed July 20, 2001. Entry of the following Amendment is respectfully requested prior to examination on the merits.

In the specification:

On pages 1-2, in the paragraph on lines 22-36 and 1-15, the text has been amended to read:

-- Various molecules, such as tumor necrosis factor- α ("TNF- α "), tumor necrosis factor- β ("TNF- β " or "lymphotoxin- α "), lymphotoxin- β ("LT- β "), CD30 ligand, CD27 ligand, CD40 ligand, OX-40 ligand, 4-1BB ligand, Apo-1 ligand (also referred to as Fas ligand or CD95 ligand), Apo-2 ligand (also referred to as TRAIL), Apo-3 ligand (also referred to as TWEAK), osteoprotegerin (OPG),

AL

08/21/2001 MDANTE1 00000004 070630 09589395

01 FC:103 234.00 CH
02 FC:102 80.00 CH